Evidence map›Paper›PMID 40992762›Full record

ReviewYonsei medical journal2025

Acidic Tumor Microenvironments and Emerging Therapeutic Strategies for Cancer Therapy.

Yongzhi Zhuang, Liquan Tong, Xueying Sun

Abstract readReview
In one paragraph

Review in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Cancers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yongzhi ZhuangDepartment of Oncology, the Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang, China.ORCID https://orcid.org/0009-0000-7310-0529
Liquan TongDepartment of General Surgery, the Fifth Affiliated Hospital of Harbin Medical University, Daqing, Heilongjiang, China.ORCID https://orcid.org/0000-0002-1970-6674
Xueying SunDepartment of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, the University of Auckland, Auckland, New Zealand. k.sun@auckland.ac.nz.ORCID https://orcid.org/0000-0002-8065-8747

Funding

Fifth Affiliated Hospital of Harbin Medical University 2022-002Fifth Affiliated Hospital of Harbin Medical University 2023-001National Key Research and Development Program of China 2017YFC1308602
6 · The paper itself

Abstract

Hypoxia and acidity represent two distinct properties of tumor microenvironments (TMEs). Tumor acidity was initially proposed to be a "by-product" of hypoxia, which results from abnormal vasculature and excessive oxygen demands. It is now recognized that acidity has its unique function in TMEs, as it can exacerbate abnormal cellular energy metabolism, inhibit cellular carcinogen metabolism, impede DNA damage repair mechanisms, and suppress immune cell activation, all of which play crucial roles during carcinogenesis. Acidic TMEs are also major contributors to the invasion and metastasis of tumor cells, and participate in the mechanisms underlying resistance to cancer treatments including immunotherapy. Therefore, the development of novel anti-cancer agents that target acidic TMEs may have considerable clinical benefits. This article reviews the updated information in this rapidly growing field, including the influence of acidic TMEs on cancer progression, resistance to current treatments and anti-cancer immunity, and their association with hypoxia and aerobic glycolysis. It also summarizes the key molecules that contribute to acidic TMEs and highlights the development of anti-cancer agents targeting tumor acidity, primarily inhibitors of carbonic anhydrases, monocarboxylic acid transporters, vacuolar-type adenosine triphosphatase (V-ATPase), and Na

Indexed as

NeoplasmsTumor MicroenvironmentAnimalsAntineoplastic AgentsHumansAntineoplastic Agentsacidityantineoplastic agentsglycolysishypoxiaTumor microenvironments

Identifiers

PMID40992762
PMCPMC12479195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.